Muna Bhanji, Director at Intellia Therapeutics, Inc. (NTLA), sold 265 shares at $8.50 ($2K) on 2025-04-29, disclosed to the SEC on 2025-05-01.
Scheduled sale ($2k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CYTK | SELL | 2025-05-15 | $43K | — | Filing → |
| NTLA | SELL | 2025-01-31 | $3K | — | Filing → |
| VCYT | SELL | 2024-06-11 | $157K | — | Filing → |